• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肿瘤学金标准：关于单克隆抗体在头颈部鳞状细胞癌管理中应用的实用共识建议

Oncology Gold Standard practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

作者信息

Babu Govind, Bahl Ankur, Bhattacharya G S, Bhowmik K T, Dattatraya P S, Ghadyalpatil Nikhil, Karandikar S M, Kulkarni Padmaj, Sridharan Nithya, Parikh Purvish, Prabhash Kumar, Raja T, Rajasundaram S, Subramanian S, Talapatra Kaustav, Vaid Ashok

机构信息

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.

Department of Medical Oncology, Max Hospital, New Delhi, India.

出版信息

South Asian J Cancer. 2017 Oct-Dec;6(4):154-160. doi: 10.4103/sajc.sajc_181_17.

DOI:10.4103/sajc.sajc_181_17
PMID:29404293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5763625/
Abstract

We present the 2017 Oncology Gold Standard Practical Consensus Recommendation for use of monoclonal antibodies in the management of advanced squamous cell carcinoma of head neck region.

摘要

我们提出了《2017年肿瘤学金标准实用共识建议》，用于指导单克隆抗体在头颈部晚期鳞状细胞癌治疗中的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d0/5763625/02fdfc2f3694/SAJC-6-154-g005.jpg

相似文献

1
Oncology Gold Standard practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.肿瘤学金标准：关于单克隆抗体在头颈部鳞状细胞癌管理中应用的实用共识建议
South Asian J Cancer. 2017 Oct-Dec;6(4):154-160. doi: 10.4103/sajc.sajc_181_17.
2
Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.接受西妥昔单抗联合放疗治疗局部晚期头颈部鳞状细胞癌患者的放射性皮炎管理：修订分级系统和共识管理指南的建议。
Ann Oncol. 2011 Oct;22(10):2191-200. doi: 10.1093/annonc/mdr139. Epub 2011 May 23.
3
Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.头颈部局部晚期鳞状细胞癌患者接受西妥昔单抗和放疗时的皮炎管理。
Oral Oncol. 2012 Apr;48(4):293-7. doi: 10.1016/j.oraloncology.2011.10.019. Epub 2011 Dec 3.
4
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines.喉、下咽、口咽和口腔鳞状细胞癌的原发肿瘤临床靶区（CTV-P）勾画：AIRO、CACA、DAHANCA、EORTC、GEORCC、GORTEC、HKNPCSG、HNCIG、IAG-KHT、LPRHHT、NCIC CTG、NCRI、NRG Oncology、PHNS、SBRT、SOMERA、SRO、SSHNO、TROG 共识指南。
Radiother Oncol. 2018 Jan;126(1):3-24. doi: 10.1016/j.radonc.2017.10.016. Epub 2017 Nov 24.
5
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.亚洲国家头颈部癌症管理的共识建议：国际指南综述。
Oral Oncol. 2013 Sep;49(9):872-877. doi: 10.1016/j.oraloncology.2013.05.010. Epub 2013 Jul 4.
6
Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.表皮生长因子受体作为癌症治疗靶点：IMC-C225在肺癌和头颈癌治疗中的新作用
Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36. doi: 10.1053/sonc.2002.31525.
7
Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma.《肿瘤学黄金标准™ 2016年晚期透明细胞肾细胞癌治疗实用共识推荐》
South Asian J Cancer. 2016 Oct-Dec;5(4):167-175. doi: 10.4103/2278-330X.189933.
8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.帕博利珠单抗对比甲氨蝶呤、多西他赛或西妥昔单抗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-040）：一项随机、开放标签、III 期研究。
Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30.
9
[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].[头颈部肿瘤的初始治疗研究结果：2016年美国临床肿瘤学会年会要点]
HNO. 2016 Oct;64(10):717-22. doi: 10.1007/s00106-016-0243-6.
10
Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.帕尼单抗联合放疗对比放化疗用于治疗不可切除的局部晚期头颈部鳞状细胞癌患者（CONCERT-2）：一项随机、对照、开放标签的 2 期临床试验。
Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15.

引用本文的文献

1
An optical aptasensor for real-time quantification of endotoxin: From ensemble to single-molecule resolution.一种用于实时定量内毒素的光学适体传感器：从集合体到单分子分辨率。
Sci Adv. 2023 Feb 10;9(6):eadf5509. doi: 10.1126/sciadv.adf5509. Epub 2023 Feb 8.
2
Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.泛亚地区适用的 EHNS-ESMO-ESTRO 临床实践指南：头颈部鳞状细胞癌的诊断、治疗和随访。
ESMO Open. 2021 Dec;6(6):100309. doi: 10.1016/j.esmoop.2021.100309. Epub 2021 Nov 26.
3
Editorial.

本文引用的文献

1
Durvalumab: First Global Approval.度伐利尤单抗：全球首次获批。
Drugs. 2017 Aug;77(12):1369-1376. doi: 10.1007/s40265-017-0782-5.
2
Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.西妥昔单抗联合化疗治疗复发和转移性头颈癌的疗效与毒性：一项前瞻性观察研究。
Indian J Cancer. 2016 Oct-Dec;53(4):487-492. doi: 10.4103/ijc.IJC_7_17.
3
Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline.
社论。
South Asian J Cancer. 2018 Apr-Jun;7(2):67-68. doi: 10.4103/sajc.sajc_144_18.
口咽鳞状细胞癌的放射治疗：美国放射肿瘤学会循证临床实践指南执行摘要
Pract Radiat Oncol. 2017 Jul-Aug;7(4):246-253. doi: 10.1016/j.prro.2017.02.002. Epub 2017 Apr 17.
4
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.在铂类敏感和不敏感的头颈癌中，使用紫杉醇和西妥昔单抗作为姑息性化疗的三级医疗经验。
South Asian J Cancer. 2017 Jan-Mar;6(1):11-14. doi: 10.4103/2278-330X.202558.
5
A retrospective analysis of patients with head and neck cancer treated with radiation, hyperthermia, and cetuximab: A brief report of outcome.对头颈部癌患者采用放疗、热疗和西妥昔单抗治疗的回顾性分析：疗效简要报告
J Cancer Res Ther. 2016 Jul-Sep;12(3):1164-1166. doi: 10.4103/0973-1482.194600.
6
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial.顺铂同步标准放疗与帕尼单抗同步加速放疗治疗局部晚期头颈部鳞状细胞癌的疗效：一项随机临床试验
JAMA Oncol. 2017 Feb 1;3(2):220-226. doi: 10.1001/jamaoncol.2016.4510.
7
Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population.局部晚期头颈癌患者中每周顺铂同步放疗与西妥昔单抗同步放疗的比较：亚洲人群的首项回顾性研究
Asia Pac J Clin Oncol. 2017 Jun;13(3):195-203. doi: 10.1111/ajco.12581. Epub 2016 Nov 3.
8
Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.西妥昔单抗联合放疗对比顺铂联合放疗治疗局部晚期头颈部鳞癌：一项随机 II 期试验。
J Clin Oncol. 2016 Feb 10;34(5):427-35. doi: 10.1200/JCO.2015.63.1671. Epub 2015 Dec 7.
9
Chemoradiation in elderly patients with head and neck cancers: a single institution experience.老年头颈癌患者的放化疗：单机构经验
Am J Otolaryngol. 2015 Mar-Apr;36(2):117-21. doi: 10.1016/j.amjoto.2014.07.015. Epub 2014 Sep 19.
10
Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.同步加速放疗联合顺铂加或不加西妥昔单抗治疗Ⅲ至Ⅳ期头颈部癌的随机Ⅲ期试验：RTOG 0522
J Clin Oncol. 2014 Sep 20;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633.